表紙
市場調査レポート

動脈硬化症:パイプライン製品の分析

Arteriosclerosis - Pipeline Review, H2 2014

発行 Global Markets Direct 商品コード 245965
出版日 ページ情報 英文 59 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
動脈硬化症:パイプライン製品の分析 Arteriosclerosis - Pipeline Review, H2 2014
出版日: 2014年07月31日 ページ情報: 英文 59 Pages
概要

アテローム性動脈硬化症(atherosclerosis)は動脈硬化症(arteriosclerosis)の一種ですが、しばしば意義を取り替えて使用されています。アテローム性動脈硬化症とは、動脈壁の内部または表面に脂肪やコレステロールが付着してプラーク(動脈硬化巣)が形成され、血流を妨げる現象を指します。

当レポートでは、世界各国での動脈硬化症治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

イントロダクション

  • 分析範囲

動脈硬化症の概要

治療薬の開発

  • 動脈硬化症向けパイプライン製品:概要
  • 動脈硬化症向けパイプライン製品:比較分析

各企業で開発中の動脈硬化症治療薬

大学/研究機関で研究中の動脈硬化症治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

動脈硬化症治療薬:開発中の製品の一覧(企業別)

動脈硬化症治療薬:研究中の製品の一覧(大学/研究機関別)

動脈硬化症治療薬の開発に従事している企業

  • Johnson & Johnson
  • 興和
  • 日本新薬
  • KunWha Pharmaceutical Co., Ltd
  • AnGes MG, Inc.
  • LTT Bio-Pharma Co., Ltd
  • CytoTools AG
  • Angelini Group
  • ECI, Inc

動脈硬化症:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別
  • 薬効分類別

薬剤のプロファイル

  • beperminogene perplasmid
  • ecraprost
  • K-134
  • selexipag
  • beperminogene perplasmid
  • sarpogrelate SR
  • PPARgamma修飾薬
  • アデノウイルスベクターによるヒトABCG1遺伝子治療
  • LT-0101
  • HMW02Ak
  • LMW-0x
  • FROUNT阻害剤
  • VE-Statin

動脈硬化症治療薬:最新の薬剤プロファイル

動脈硬化症治療薬:開発が休止状態の製品

動脈硬化症治療薬:開発が中止された製品

動脈硬化症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全10件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC5260IDB

Summary

Global Markets Direct's, 'Arteriosclerosis - Pipeline Review, H2 2014', provides an overview of the Arteriosclerosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Arteriosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arteriosclerosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Arteriosclerosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Arteriosclerosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Arteriosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Arteriosclerosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Arteriosclerosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Arteriosclerosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Arteriosclerosis Overview
  • Therapeutics Development
    • Pipeline Products for Arteriosclerosis - Overview
    • Pipeline Products for Arteriosclerosis - Comparative Analysis
  • Arteriosclerosis - Therapeutics under Development by Companies
  • Arteriosclerosis - Therapeutics under Investigation by Universities/Institutes
  • Arteriosclerosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Arteriosclerosis - Products under Development by Companies
  • Arteriosclerosis - Products under Investigation by Universities/Institutes
  • Arteriosclerosis - Companies Involved in Therapeutics Development
    • Johnson & Johnson
    • Kowa Company, Ltd.
    • Nippon Shinyaku Co., Ltd.
    • KunWha Pharmaceutical Co., Ltd.
    • AnGes MG, Inc.
    • LTT Bio-Pharma Co., Ltd.
    • CytoTools AG
  • Arteriosclerosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • beperminogene perplasmid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ecraprost - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • K-134 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • selexipag - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sarpogrelate SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LMW-0x - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Arteriosclerosis and Endothelial Dysfunction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-0101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VE-Statin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Arteriosclerosis - Recent Pipeline Updates
  • Arteriosclerosis - Dormant Projects
  • Arteriosclerosis - Discontinued Products
  • Arteriosclerosis - Product Development Milestones
    • Featured News & Press Releases
      • May 01, 2014: The Medicines Company and Alnylam Announce Presentation of New Pre-Clinical Data on PCSK9 at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions
      • Nov 15, 2012: AtheroNova Receives Notice Of Issuance Of U.S. Patent 8,304,383
      • Nov 02, 2012: AlphaCore Receives Orphan Drug Designation For ACP-501 From European Medicines Agency
      • Aug 26, 2012: Merck Provides Update On Tredaptive Development Program
      • Jul 09, 2012: AtheroNova Receives Notice Of Allowance For US Patent Application 12/024,908
      • Apr 25, 2012: Frontage Signs Agreement For Development Of Clinical Trial Supplies
      • Nov 02, 2011: Resverlogix Commences Dosing In ASSURE Phase IIb IVUS Clinical Trial Targeting High-Risk Cardiovascular Disease Patients
      • Mar 21, 2011: FDA Accepts Arisaph's Investigational New Drug Application For Dyslipidemia Drug
      • Jan 04, 2011: AnGes MG Announces Publication Of Collategene Clinical Research Data In Arteriosclerosis, Thrombosis And Vascular Biology
      • Jul 26, 2010: Cerenis And Novasep Receive EUR10.7 Million Funding From French Government For Development Of CER-001
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Arteriosclerosis, H2 2014
  • Number of Products under Development for Arteriosclerosis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Arteriosclerosis - Pipeline by Johnson & Johnson, H2 2014
  • Arteriosclerosis - Pipeline by Kowa Company, Ltd., H2 2014
  • Arteriosclerosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2014
  • Arteriosclerosis - Pipeline by KunWha Pharmaceutical Co., Ltd., H2 2014
  • Arteriosclerosis - Pipeline by AnGes MG, Inc., H2 2014
  • Arteriosclerosis - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2014
  • Arteriosclerosis - Pipeline by CytoTools AG, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Arteriosclerosis Therapeutics - Recent Pipeline Updates, H2 2014
  • Arteriosclerosis - Dormant Projects, H2 2014
  • Arteriosclerosis - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Arteriosclerosis, H2 2014
  • Number of Products under Development for Arteriosclerosis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top